Compile Data Set for Download or QSAR
maximum 50k data
Found 34 Enz. Inhib. hit(s) with all data for entry = 11319
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606867(US11685738, Compound A3)
Affinity DataIC50:  0.570nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606865(US11685738, Compound A4)
Affinity DataIC50:  1.40nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606917(US11685738, Compound A23)
Affinity DataIC50:  4.30nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606955(US11685738, Compound A21-2)
Affinity DataIC50:  4.60nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606865(US11685738, Compound A4)
Affinity DataIC50:  5.69nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606947(US11685738, Compound A15s)
Affinity DataIC50:  5.92nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606954(US11685738, Compound A21 | acid )
Affinity DataIC50:  7.64nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606883(US11685738, Compound A6)
Affinity DataIC50:  8.25nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606864(US11685738, Compound A1)
Affinity DataIC50:  8.30nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606866(US11685738, Compound A2)
Affinity DataIC50:  9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606947(US11685738, Compound A15s)
Affinity DataIC50:  9.28nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM50134778((S)-3-(6-Methoxy-pyridin-3-yl)-3-{2-oxo-3-[3-(5,6,...)
Affinity DataIC50:  9.57nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606881(US11685738, Compound A5)
Affinity DataIC50:  9.97nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606866(US11685738, Compound A2)
Affinity DataIC50:  11.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606884(US11685738, Compound A7)
Affinity DataIC50:  11.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606864(US11685738, Compound A1)
Affinity DataIC50:  13.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606917(US11685738, Compound A23)
Affinity DataIC50:  14.8nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606919(US11685738, Compound A28 | acid )
Affinity DataIC50:  16.9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606918(US11685738, Compound A24 | acid )
Affinity DataIC50:  17.5nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM50134778((S)-3-(6-Methoxy-pyridin-3-yl)-3-{2-oxo-3-[3-(5,6,...)
Affinity DataIC50:  17.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606867(US11685738, Compound A3)
Affinity DataIC50:  18.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606865(US11685738, Compound A4)
Affinity DataIC50:  21.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606883(US11685738, Compound A6)
Affinity DataIC50:  24nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606919(US11685738, Compound A28 | acid )
Affinity DataIC50:  34.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606918(US11685738, Compound A24 | acid )
Affinity DataIC50:  35.4nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606955(US11685738, Compound A21-2)
Affinity DataIC50:  50.3nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606881(US11685738, Compound A5)
Affinity DataIC50:  63.9nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606881(US11685738, Compound A5)
Affinity DataIC50:  65.7nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606866(US11685738, Compound A2)
Affinity DataIC50:  78.1nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606867(US11685738, Compound A3)
Affinity DataIC50:  79.3nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606884(US11685738, Compound A7)
Affinity DataIC50:  80.6nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606954(US11685738, Compound A21 | acid )
Affinity DataIC50:  88.2nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-8(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606917(US11685738, Compound A23)
Affinity DataIC50:  151nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Ocuterra Therapeutics

US Patent
LigandPNGBDBM606883(US11685738, Compound A6)
Affinity DataIC50:  190nMAssay Description:The full reaction (Integrin-Ligand Interaction) was optimized as above. Integrin coupled beads were taken for the experiment. 2 μL of 10 nM/20 n...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent